In a recent decision, the Federal Circuit upheld a lower court’s preliminary injunction that prohibits Celltrion Inc., a South Korean pharmaceutical company, from launching a biosimilar of Regeneron’s widely-used eye disease medication, Eylea. The court dismissed Celltrion’s claims regarding the potential invalidity of a patent associated with the drug.
More details can be found in the original Law360 reporting.
The ruling represents a significant obstacle for Celltrion, which had aimed to enter the biosimilar market with a competitor to Regeneron’s successful treatment. The decision underscores the complexities and challenges companies face when navigating patent laws and seeking to introduce alternative versions of existing biologic drugs.